Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama
A Randomized, Double-blind, Pivotal Phase 3 Study of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Alone Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama
Sponsor: U.S. Army Medical Research and Development Command
A PHASE3 clinical study on Cutaneous Leishmaniasis, this trial is completed. The trial is conducted by U.S. Army Medical Research and Development Command and has accumulated 10 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Aug 2019 [monthly]
Completed PHASE3
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Sep 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
May 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- U.S. Army Medical Research and Development Command
For direct contact, visit the study record on ClinicalTrials.gov .